{"id":"https://openalex.org/W3211568627","doi":"https://doi.org/10.1182/blood-2021-146570","title":"Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia","display_name":"Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3211568627","doi":"https://doi.org/10.1182/blood-2021-146570","mag":"3211568627"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-146570","doi":"https://doi.org/10.1182/blood-2021-146570","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-146570","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krakow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krakow, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112473883","display_name":"Andrzej Pluta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrzej Pluta","raw_affiliation_strings":["Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063922698","display_name":"Ma\u0142gorzata Wach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121032520","display_name":"Medical University of Lublin","ror":"https://ror.org/016f61126","country_code":"PL","type":"education","lineage":["https://openalex.org/I121032520"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Malgorzata Wach","raw_affiliation_strings":["Department of Hemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland","institution_ids":["https://openalex.org/I121032520"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068758499","display_name":"Daniel Lys\u00e1k","orcid":"https://orcid.org/0000-0001-9391-4247","observed_orcids":["https://orcid.org/0000-0001-9391-4247"]},"institutions":[{"id":"https://openalex.org/I4210113757","display_name":"University Hospital Plzen","ror":"https://ror.org/02c1tfz23","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I21250087","https://openalex.org/I4210113757"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Daniel Lysak","raw_affiliation_strings":["Fakultn\u00ed Nemocnice Plzen, Pilsen, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fakultn\u00ed Nemocnice Plzen, Pilsen, Czech Republic","institution_ids":["https://openalex.org/I4210113757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102919781","display_name":"Tom\u00e1\u0161 Koz\u00e1k","orcid":"https://orcid.org/0009-0005-2446-7988","observed_orcids":["https://orcid.org/0009-0005-2446-7988"]},"institutions":[{"id":"https://openalex.org/I4210156160","display_name":"University Hospital Kralovske Vinohrady","ror":"https://ror.org/04sg4ka71","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I4210156160"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Tomas Kozak","raw_affiliation_strings":["Fakultn\u00ed Nemocnice Kr\u00e1lovske Vinohrady, Prague, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fakultn\u00ed Nemocnice Kr\u00e1lovske Vinohrady, Prague, Czech Republic","institution_ids":["https://openalex.org/I4210156160"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077793241","display_name":"Martin \u0160imkovi\u010d","orcid":"https://orcid.org/0000-0003-0331-5334","observed_orcids":["https://orcid.org/0000-0003-0331-5334"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]},{"id":"https://openalex.org/I4210137570","display_name":"University Hospital Hradec Kr\u00e1lov\u00e9","ror":"https://ror.org/04wckhb82","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I4210137570"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Martin \u0160imkovi\u010d","raw_affiliation_strings":["University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic","institution_ids":["https://openalex.org/I21250087","https://openalex.org/I4210137570"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023781725","display_name":"Iryna Kriachok","orcid":"https://orcid.org/0000-0002-8141-0735","observed_orcids":["https://orcid.org/0000-0002-8141-0735"]},"institutions":[{"id":"https://openalex.org/I4210123359","display_name":"National Cancer Institute","ror":"https://ror.org/02t771148","country_code":"UA","type":"facility","lineage":["https://openalex.org/I4210123359"]}],"countries":["UA"],"is_corresponding":false,"raw_author_name":"Iryna Kriachok","raw_affiliation_strings":["National Cancer Institute, Kiev, Ukraine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Institute, Kiev, Ukraine","institution_ids":["https://openalex.org/I4210123359"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012342629","display_name":"\u00c1rp\u00e1d Ill\u00e9s","orcid":"https://orcid.org/0000-0001-6548-2926","observed_orcids":["https://orcid.org/0000-0001-6548-2926"]},"institutions":[{"id":"https://openalex.org/I132735039","display_name":"University of Debrecen","ror":"https://ror.org/02xf66n48","country_code":"HU","type":"education","lineage":["https://openalex.org/I132735039"]}],"countries":["HU"],"is_corresponding":false,"raw_author_name":"Arpad Illes","raw_affiliation_strings":["Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary","institution_ids":["https://openalex.org/I132735039"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082366310","display_name":"Javier de la Serna","orcid":"https://orcid.org/0000-0003-3904-1101","observed_orcids":["https://orcid.org/0000-0003-3904-1101"]},"institutions":[{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Javier de la Serna","raw_affiliation_strings":["Hospital Universitario 12 de Octubre, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario 12 de Octubre, Madrid, Spain","institution_ids":["https://openalex.org/I4210101691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112050623","display_name":"Sean Dolan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I106938459","display_name":"University of New Brunswick","ror":"https://ror.org/05nkf0n29","country_code":"CA","type":"education","lineage":["https://openalex.org/I106938459"]},{"id":"https://openalex.org/I2800296662","display_name":"Saint John Regional Hospital","ror":"https://ror.org/05k4mr860","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2800296662"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Sean Dolan","raw_affiliation_strings":["Saint John Regional Hospital, University of New Brunswick, New Brunswick, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint John Regional Hospital, University of New Brunswick, New Brunswick, Canada","institution_ids":["https://openalex.org/I106938459","https://openalex.org/I2800296662"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080443755","display_name":"Philip J. Campbell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I132157203","display_name":"Barwon Health","ror":"https://ror.org/00my0hg66","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I132157203"]},{"id":"https://openalex.org/I2799712879","display_name":"Geelong Hospital","ror":"https://ror.org/00jrpxe15","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I132157203","https://openalex.org/I2799712879"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Philip Campbell","raw_affiliation_strings":["Barwon Health, University Hospital Geelong, Geelong, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barwon Health, University Hospital Geelong, Geelong, Australia","institution_ids":["https://openalex.org/I132157203","https://openalex.org/I2799712879"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082964368","display_name":"Gerardo Musuraca","orcid":"https://orcid.org/0000-0003-1947-1032","observed_orcids":["https://orcid.org/0000-0003-1947-1032"]},"institutions":[{"id":"https://openalex.org/I4210097834","display_name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori","ror":"https://ror.org/013wkc921","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210097834","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Gerardo Musuraca","raw_affiliation_strings":["Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy","institution_ids":["https://openalex.org/I4210097834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033489159","display_name":"Abraham O. Jacob","orcid":"https://orcid.org/0000-0001-6899-5049","observed_orcids":["https://orcid.org/0000-0001-6899-5049"]},"institutions":[{"id":"https://openalex.org/I4210154310","display_name":"The Royal Wolverhampton NHS Trust","ror":"https://ror.org/05pjd0m90","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210154310"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Abraham Jacob","raw_affiliation_strings":["The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom","institution_ids":["https://openalex.org/I4210154310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073166113","display_name":"Eric Joseph Avery","orcid":"https://orcid.org/0000-0002-0480-0721","observed_orcids":["https://orcid.org/0000-0002-0480-0721"]},"institutions":[{"id":"https://openalex.org/I4210151829","display_name":"Nebraska Hematology-Oncology","ror":"https://ror.org/05gctgr03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210151829"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric J. Avery","raw_affiliation_strings":["Nebraska Hematology Oncology, Lincoln, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nebraska Hematology Oncology, Lincoln, NE","institution_ids":["https://openalex.org/I4210151829"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100387458","display_name":"Jae Hoon Lee","orcid":"https://orcid.org/0000-0002-1342-3104","observed_orcids":["https://orcid.org/0000-0002-1342-3104"]},"institutions":[{"id":"https://openalex.org/I4210088426","display_name":"Gachon University Gil Medical Center","ror":"https://ror.org/005nteb15","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I12832649","https://openalex.org/I4210088426"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Jae Hoon Lee","raw_affiliation_strings":["Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)","institution_ids":["https://openalex.org/I4210088426"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087424125","display_name":"Min Hui Wang","orcid":"https://orcid.org/0000-0002-2073-5392","observed_orcids":["https://orcid.org/0000-0002-2073-5392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Min Hui Wang","raw_affiliation_strings":["AstraZeneca, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, South San Francisco, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108576759","display_name":"Ting Yu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ting Yu","raw_affiliation_strings":["AstraZeneca, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, South San Francisco, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[{"id":"https://openalex.org/I154387261","display_name":"Vita-Salute San Raffaele University","ror":"https://ror.org/01gmqr298","country_code":"IT","type":"education","lineage":["https://openalex.org/I154387261"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":["Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy","institution_ids":["https://openalex.org/I154387261"]}]}],"institutions":[],"countries_distinct_count":11,"institutions_distinct_count":18,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"393","last_page":"393"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.9679999947547913},{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":1.0},{"id":"https://openalex.org/keywords/bendamustine-plus-rituximab","display_name":"bendamustine-rituximab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8410000205039978},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9919999837875366},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.8650000095367432},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.6759999990463257},{"id":"https://openalex.org/keywords/ascend-trial","display_name":"ASCEND trial","score":0.6039999723434448},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.5770000219345093},{"id":"https://openalex.org/keywords/unmutated-ighv","display_name":"unmutated IGHV","score":0.8090000152587891}],"concepts":[{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.8733309507369995},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7607412338256836},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.7435002326965332},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.677426278591156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6685458421707153},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6246345639228821},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5014429092407227},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.49434661865234375},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.49148380756378174},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.41629183292388916},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3919847011566162},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.37268781661987305},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.2571738064289093},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.25635045766830444},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.24956974387168884},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.13556286692619324},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-146570","doi":"https://doi.org/10.1182/blood-2021-146570","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-146570","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4281953617","https://openalex.org/W4283328977","https://openalex.org/W3112032975","https://openalex.org/W3028905201","https://openalex.org/W3029637120","https://openalex.org/W4308963956","https://openalex.org/W3134012358","https://openalex.org/W2951808700","https://openalex.org/W2984259387","https://openalex.org/W3137497137"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Bruton":[2],"tyrosine":[3],"kinase":[4],"(BTK)":[5],"inhibitors":[6],"are":[7,458],"a":[8,24,53,244,631,934,977,1029],"preferred":[9],"treatment":[10,34,456,530],"option":[11],"in":[12,84,194,339,342,409,450,454,460,510,524,528,560,638,729,778,924,933,939,976,982,994,1007,1021,1028,1034],"patients":[13,36,85,119,195,221,343,375,453,527,639],"with":[14,37,41,52,68,86,120,344,376,429,433,439,470,485,493,640,650,656],"relapsed/refractory":[15],"(R/R)":[16],"chronic":[17],"lymphocytic":[18],"leukemia":[19],"(CLL).":[20],"Acalabrutinib":[21],"(acala)":[22],"is":[23],"next-generation,":[25],"highly":[26],"selective,":[27],"covalent":[28],"BTK":[29],"inhibitor":[30],"approved":[31],"for":[32,156,176,260,296,300,309,369,400,418,422],"the":[33,45,49,101,188,345,412,461,463,623,730,779,940,983,1008,1035],"of":[35,48,57,100,107,139,219,248,452,512,515,519,526,562,565,569,573,621,625,708,739,768,804,909,950,963],"CLL":[38,88,122],"including":[39,436],"those":[40],"R/R":[42,87,121,641],"disease.":[43],"In":[44,110,374],"primary":[46,607],"analysis":[47],"ASCEND":[50,102],"study":[51,103,117],"median":[54,245,348,379],"follow-up":[55,247],"duration":[56],"16.1":[58,384],"months,":[59,278],"acala":[60,128,189,261,265,297,310,370,401,419,430,471,626],"monotherapy":[61,190,627],"demonstrated":[62],"superior":[63],"progression-free":[64],"survival":[65,207],"(PFS)":[66],"compared":[67],"idelalisib":[69],"(Id)":[70],"plus":[71,78],"rituximab":[72],"(R)":[73],"(IdR)":[74],"or":[75,135,160,183,200,710,806,911,936,952,965,979,1031],"bendamustine":[76],"(B)":[77],"R":[79],"(BR)":[80],"and":[81,167,214,251,262,319,367,371,398,402,479,489,492,502,517,547,567,604,1014],"favorable":[82],"safety":[83,653],"(Ghia":[89],"et":[90],"al.":[91],"J":[92],"Clin":[93],"Oncol.":[94],"2020;38:2849-2861).":[95],"Herein":[96],"we":[97],"report":[98],"results":[99],"at":[104],"3":[105,116,619],"years":[106,620],"follow-up.":[108,658],"Methods:":[109],"this":[111],"randomized,":[112],"multicenter,":[113],"open-label,":[114],"phase":[115],"(NCT02970318),":[118],"were":[123,228,294,307,365,396,472,508,532],"randomized":[124],"1:1":[125],"to":[126,187,557],"receive":[127],"100":[129],"mg":[130,143],"orally":[131],"(PO)":[132],"twice":[133,145],"daily":[134],"investigator's":[136],"(INV)":[137],"choice":[138],"IdR":[140,199,312,536,543,551],"(Id:":[141],"150":[142],"PO":[144],"daily;":[146],"R:":[147,168],"375":[148,169],"x1":[149,170],"then":[150,171],"500":[151,172],"mg/m":[152,164,173],"2":[153,165,174],"intravenously":[154],"[IV]":[155],"8":[157],"total":[158,178,218],"infusions)":[159],"BR":[161,321,520,538,545,553,570],"(B:":[162],"70":[163],"IV":[166,175],"6":[177],"cycles)":[179],"until":[180],"disease":[181],"progression":[182],"unacceptable":[184],"toxicity.":[185],"Crossover":[186],"arm":[191,457,531],"was":[192,335,350,381,407,416,427,441,628],"permitted":[193],"who":[196],"progressed":[197],"on":[198,704,800,905,946,959],"BR.":[201],"Assessments":[202],"included":[203,576],"INV-assessed":[204,209,268],"PFS,":[205],"overall":[206,210],"(OS),":[208],"response":[211,438],"rate":[212,415],"(ORR),":[213],"safety.":[215],"Results:":[216],"A":[217],"310":[220],"(acala,":[222],"n=155;":[223],"IdR,":[224,486,516,566],"n=119;":[225],"BR,":[226,494],"n=36)":[227],"enrolled":[229],"(median":[230],"age:":[231],"67":[232],"y;":[233],"del(17p)":[234,346],"16%,":[235],"unmutated":[236,377],"IGHV":[237],"78%,":[238],"Rai":[239],"stage":[240],"3/4":[241],"42%).":[242],"At":[243,618],"(range)":[246],"36.0":[249],"(0.5-44.0)":[250],"35.2":[252],"(0.03-42.5)":[253],"months":[254,315,324,354,385],"(data":[255],"cutoff:":[256],"October":[257],"26,":[258],"2020)":[259],"IdR/BR,":[263,372,403],"respectively,":[264],"significantly":[266],"prolonged":[267],"PFS":[269,292,305,333,349,363,380,394,633],"vs":[270,276,298,311,320,352,383,420,431,443],"IdR/BR":[271,301,423,434,582,588,595,602,615],"(median:":[272,313,322],"not":[273],"reached":[274],"[NR]":[275],"16.8":[277],"respectively;":[279],"hazard":[280],"ratio":[281],"[HR]:":[282],"0.29;":[283],"95%":[284,357,388],"confidence":[285],"interval":[286],"[CI]:":[287],"0.21,":[288,390],"0.41;":[289],"P<0.0001);":[290,361,392],"36-month":[291,362,393,413],"rates":[293,364,395],"63%":[295,514],"21%":[299,561],"(Figure":[302,331,424],"1).":[303],"Similar":[304],"benefits":[306],"observed":[308],"16.2":[314],"[HR:":[316,325],"0.31;":[317],"P<0.0001])":[318,327],"18.6":[323],"0.25;":[326],"when":[328],"assessed":[329],"separately":[330],"2).":[332],"benefit":[334,634],"also":[336,644],"consistently":[337],"shown":[338,459],"high-risk":[340],"subgroups;":[341],"mutation,":[347],"NR":[351,382,408],"13.8":[353],"(HR:":[355,386],"0.13;":[356],"CI:":[358,389],"0.06,":[359],"0.3;":[360],"66%":[366],"5%":[368],"respectively.":[373,404],"IGHV,":[378],"0.30;":[387],"0.42;":[391],"61%":[397],"17%":[399,568],"Median":[405],"OS":[406,414],"both":[410],"arms;":[411],"80%":[417],"73%":[421],"3).":[425],"ORR":[426],"83%":[428],"85%":[432],"(ORR":[435],"partial":[437],"lymphocytosis":[440],"92%":[442],"88%,":[444],"respectively).":[445],"Adverse":[446],"events":[447],"(AEs)":[448],"occurring":[449],"\u226515%":[451],"any":[455,529],"Table;":[462],"most":[464],"commonly":[465],"reported":[466,509,523],"all-grade":[467,577,584,590,605],"AEs":[468,506,555],"(\u226520%)":[469],"headache":[473],"(23%),":[474,476,498,501],"neutropenia":[475,490,495],"diarrhea":[477,487,548],"(21%),":[478],"upper":[480],"respiratory":[481],"tract":[482],"infection":[483],"(20%);":[484],"(53%)":[488],"(47%);":[491],"(34%),":[496],"fatigue":[497],"infusion-related":[499],"reaction":[500],"nausea":[503],"(20%).":[504],"Serious":[505],"(SAEs)":[507],"38%":[511],"acala,":[513,563],"26%":[518],"patients;":[521],"SAEs":[522],"\u22655%":[525],"pneumonia":[533],"(acala":[534,541,549,580,586,593,600,613],"8%,":[535],"9%,":[537],"3%),":[539,546,583,596],"pyrexia":[540],"2%,":[542],"7%,":[544,587,614],"1%,":[550],"15%,":[552],"0%).":[554],"led":[556],"drug":[558],"discontinuation":[559],"65%":[564],"patients.":[571],"Events":[572],"clinical":[574],"interest":[575],"atrial":[578],"fibrillation/flutter":[579],"6%,":[581],"hypertension":[585],"4%),":[589],"major":[591],"hemorrhage":[592],"3%,":[594],"grade":[597],"\u22653":[598],"infections":[599],"25%,":[601],"27%),":[603],"second":[606],"malignancies":[608],"excluding":[609],"non-melanoma":[610],"skin":[611],"cancer":[612],"3%).":[616],"Conclusions:":[617],"follow-up,":[622],"efficacy":[624],"maintained,":[629],"showing":[630],"significant":[632],"over":[635],"standard-of-care":[636],"regimens":[637],"CLL.":[642],"Acala":[643],"maintained":[645],"an":[646,705,801,906,947,960],"acceptable":[647],"tolerability":[648],"profile":[649],"no":[651],"new":[652],"findings":[654],"identified":[655],"longer-term":[657],"Figure":[659,661],"1":[660],"1.":[662],"Disclosures":[663],"Jurczak:":[664],"AbbVie,":[665,792,856,866,968,1016],"AstraZeneca,":[666,696,793,857,867,1012],"Bayer,":[667],"BeiGene,":[668,697,720,762],"Celtrion,":[669],"Celgene,":[670,744,843],"Debbiopharm,":[671],"Epizyme,":[672,721],"Incyte,":[673,915],"Janssen,":[674,698,816,822,830,842,861,897,901,914],"Loxo":[675,699],"Oncology,":[676,700],"Merck,":[677],"Mei":[678],"Pharma,":[679,760],"Morphosys,":[680],"Novo":[681],"Nordisk,":[682],"Roche,":[683,758,814,820,898,902],"Sandoz,":[684,701],"Takeda,":[685,746,813,819,837,846],"TG":[686],"Therapeutics,":[687,756],"Pharmacyclics,":[688,761],"Affirmed,":[689],"Gilead":[690],"Sciences,":[691],"Nordic":[692],"Nanovecto:":[693],"Research":[694,737,764,789,840,854,874,878,887,890,894,1003,1043,1048,1053,1066,1071,1077],"Funding;":[695,765,841,855,875,879,888,891,1044,1049,1054,1067,1072],"Roche:":[702,796,832,847,864,868,892,916,1073],"Membership":[703,799,904,945,958],"entity's":[706,802,907,948,961],"Board":[707,803,908,949,962],"Directors":[709,805,910,951,964],"advisory":[711,807,912,953,966],"committees;":[712,913,954,967],"European":[713],"Medicines":[714],"Agency,":[715],"Sandoz-Novartis,":[716],"Janssen":[717],"China":[718],"R&D,":[719],"Acerta,":[722],"AstraZeneca:":[723,787,883,944,988,998,1050],"Consultancy;":[724,818,865,882,884],"Jagiellonian":[725],"University:":[726],"Ended":[727,776,1005],"employment":[728,777,1006],"past":[731,780,941,984,1009,1036],"24":[732,781,942,985,1010,1037],"months;":[733,943,1011],"Maria":[734],"Sklodowska-Curie":[735],"National":[736,766],"Institute":[738],"Oncology:":[740],"Current":[741,770,921,989,991,999,1018],"Employment.":[742],"Pluta:":[743],"Servier,":[745],"Novartis:":[747,872],"Honoraria;":[748,900,1057,1060,1063,1075],"Celgene:":[749],"Other:":[750,809,833],"Travel,":[751,834],"Accommodations,":[752,835],"Expenses;":[753,836],"Janssen-Cilag,":[754,785,794],"Kartos":[755],"Iqvia,":[757],"Acerta":[759],"Takeda:":[763],"University":[767],"Sanok:":[769],"Employment;":[771,1000],"Szpital":[772],"Specjalistyczny":[773],"w":[774],"Brzozowie:":[775],"months.":[782,986,1038],"Lysak:":[783],"Novartis,":[784,829,844,863],"AbbVie;":[786],"Honoraria,":[788,798,825,1042,1047,1052,1070],"Funding.":[790,895,1078],"\u0160imkovi\u010d:":[791],"Gilead,":[795,859],"Consultancy,":[797,873,877,886,893,1041,1046,1051,1056,1059,1062,1065,1069,1074],"committees,":[808],"Travel":[810],"Grants.":[811],"Kriachok:":[812],"Abbivie,":[815],"MSD:":[817],"Abbvie,":[821],"MSD,":[823],"Pfizer:":[824],"Speakers":[826,869],"Bureau.":[827,870],"Illes:":[828],"Pfizer,":[831,845],"Seattle":[838],"Genetics:":[839],"Consultancy.":[848,917],"de":[849],"la":[850],"Serna:":[851],"ABBVIE,":[852],"ASTRAZENECA,ROCHE:":[853],"Beigene,":[858],"GSK,":[860],"Jazzpharma,":[862],"Campbell:":[871],"Janssen:":[876,1068],"CSL":[880],"Behring:":[881],"Amgen:":[885],"BMS/Celgene:":[889],"Musuraca:":[896],"Incyte:":[899,903],"Jacob:":[918],"Astrazeneca,":[919],"GlaxoSmithKilne:":[920],"equity":[922,932,975,992,1019,1027],"holder":[923,993,1020],"publicly-traded":[925,937,980,995,1022,1032],"company;":[926,1023],"Horizon":[927],"Discovery,":[928],"Oxford":[929],"Biomedica:":[930],"Divested":[931,974,1026],"private":[935,978,1030],"company":[938,981,1033],"Clinical":[955],"Haematology":[956],"Services:":[957],"Astrazeneca:":[969],"Honoraria.":[970],"Avery:":[971],"Macrogenics,":[972],"Moderna:":[973],"Wang:":[987],"Employment,":[990],"company.":[996],"Yu:":[997],"EMD":[1001],"Serono":[1002],"Institute:":[1004],"Johnson":[1013],"Johnson,":[1015],"Abbott:":[1017],"Merck":[1024],"KGaA:":[1025],"Ghia:":[1039],"AbbVie:":[1040],"Acerta/AstraZeneca:":[1045],"ArQule/MSD:":[1055],"BeiGene:":[1058],"Celgene/Juno/BMS:":[1061],"Gilead:":[1064],"Sunesis:":[1076]},"counts_by_year":[{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-11-22T00:00:00"}